Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study

C A Purdie; P Quinlan; L B Jordan; A Ashfield; S Ogston; J A Dewar; A M Thompson

doi:10.1038/bjc.2013.756

Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study

C A Purdie, P Quinlan, L B Jordan, A Ashfield, S Ogston, J A Dewar, A M Thompson

Research output: Contribution to journal › Article › peer-review

144 Citations (Scopus)

Abstract

Background:Progesterone receptor (PR) expression assessment in early invasive breast cancer remains controversial. This study sought to re-evaluate PR expression as a potential therapeutic guide in early breast cancer; particularly in oestrogen receptor (ER)-positive, lymph node (LN)-negative disease.Methods:A population cohort of 1074 patients presenting to a single Cancer Centre over 4 years (2000-2004) underwent surgery for primary invasive breast cancer with curative intent. Prospective data collection included patient demographics, pathology, ER and PR expression, HER2 status, adjuvant chemotherapy and endocrine therapy. Progesterone receptor expression was compared with (all causes) overall survival (OS), breast cancer-specific survival (BCSS) and disease-free survival (DFS).Results:Overall survival was 71.0% and BCSS was 83.0% at median follow-up of 8.34 years. Absent PR expression was significantly associated with poorer prognosis for OS, BCSS and DFS (P

Original language	English
Journal	British Journal of Cancer
Early online date	3 Dec 2013
DOIs	https://doi.org/10.1038/bjc.2013.756
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2013.756

Cite this

@article{26c4e086ad1640b0ae90a76a78d4eb43,

title = "Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study",

abstract = "Background:Progesterone receptor (PR) expression assessment in early invasive breast cancer remains controversial. This study sought to re-evaluate PR expression as a potential therapeutic guide in early breast cancer; particularly in oestrogen receptor (ER)-positive, lymph node (LN)-negative disease.Methods:A population cohort of 1074 patients presenting to a single Cancer Centre over 4 years (2000-2004) underwent surgery for primary invasive breast cancer with curative intent. Prospective data collection included patient demographics, pathology, ER and PR expression, HER2 status, adjuvant chemotherapy and endocrine therapy. Progesterone receptor expression was compared with (all causes) overall survival (OS), breast cancer-specific survival (BCSS) and disease-free survival (DFS).Results:Overall survival was 71.0% and BCSS was 83.0% at median follow-up of 8.34 years. Absent PR expression was significantly associated with poorer prognosis for OS, BCSS and DFS (P",

author = "Purdie, {C A} and P Quinlan and Jordan, {L B} and A Ashfield and S Ogston and Dewar, {J A} and Thompson, {A M}",

year = "2013",

doi = "10.1038/bjc.2013.756",

language = "English",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

}

TY - JOUR

T1 - Progesterone receptor expression is an independent prognostic variable in early breast cancer

T2 - a population-based study

AU - Purdie, C A

AU - Quinlan, P

AU - Jordan, L B

AU - Ashfield, A

AU - Ogston, S

AU - Dewar, J A

AU - Thompson, A M

PY - 2013

Y1 - 2013

N2 - Background:Progesterone receptor (PR) expression assessment in early invasive breast cancer remains controversial. This study sought to re-evaluate PR expression as a potential therapeutic guide in early breast cancer; particularly in oestrogen receptor (ER)-positive, lymph node (LN)-negative disease.Methods:A population cohort of 1074 patients presenting to a single Cancer Centre over 4 years (2000-2004) underwent surgery for primary invasive breast cancer with curative intent. Prospective data collection included patient demographics, pathology, ER and PR expression, HER2 status, adjuvant chemotherapy and endocrine therapy. Progesterone receptor expression was compared with (all causes) overall survival (OS), breast cancer-specific survival (BCSS) and disease-free survival (DFS).Results:Overall survival was 71.0% and BCSS was 83.0% at median follow-up of 8.34 years. Absent PR expression was significantly associated with poorer prognosis for OS, BCSS and DFS (P

AB - Background:Progesterone receptor (PR) expression assessment in early invasive breast cancer remains controversial. This study sought to re-evaluate PR expression as a potential therapeutic guide in early breast cancer; particularly in oestrogen receptor (ER)-positive, lymph node (LN)-negative disease.Methods:A population cohort of 1074 patients presenting to a single Cancer Centre over 4 years (2000-2004) underwent surgery for primary invasive breast cancer with curative intent. Prospective data collection included patient demographics, pathology, ER and PR expression, HER2 status, adjuvant chemotherapy and endocrine therapy. Progesterone receptor expression was compared with (all causes) overall survival (OS), breast cancer-specific survival (BCSS) and disease-free survival (DFS).Results:Overall survival was 71.0% and BCSS was 83.0% at median follow-up of 8.34 years. Absent PR expression was significantly associated with poorer prognosis for OS, BCSS and DFS (P

U2 - 10.1038/bjc.2013.756

DO - 10.1038/bjc.2013.756

M3 - Article

C2 - 24300977

SN - 0007-0920

JO - British Journal of Cancer

JF - British Journal of Cancer

ER -

Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this